Phase 2
ADC Therapeutics SA announced that the first patients have been dosed in a 100-patient pivotal Phase 2 clinical trial evaluating the efficacy and safety of ADCT-301 in patients with relapsed or refractory Hodgkin lymphoma The trial is intended to support the submission of a Biologics License Application to the U.S. Food and Drug Administration.
Findings further validate Cell Pouch and therapeutic cell performance in
MetrioPharm AG, a clinical stage biopharmaceutical company, reports positive results from its recently completed Phase II dose finding study of MP1032 in psoriasis patients.
Reata announced late Monday that the second part of its Phase II MOXIe trial met the goal of modified Friedreich’s Ataxia Rating Scale after 48 weeks of treatment.
MGB Biopharma, a biopharmaceutical company developing a novel class of anti-infectives to address the major global problem of antibiotic resistance, announces an update on progress in its Phase IIa clinical study.
With No Safety Concerns, DSMB Recommends Trial Continues; Dose Increase Planned
Faron Pharmaceuticals Oy announces feedback from the MATINS study data monitoring committee from the ongoing dose escalation study from part I of the MATINS trial.
Recruitment of 39 patients in multicenter European phase 2 trial completed ahead of schedule
Summit Therapeutics plc announced the presentation of new data that explain the link between two key findings in the Company’s Phase 2 clinical trial of ridinilazole for C. difficile infection
Hutchison China MediTech Limited has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase inhibitor, in patients with relapsed or refractory lymphoma.
PRESS RELEASES